Cullinan Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Cullinan Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and vote on executive compensation.
NASDAQ
DEFA14A: Cullinan Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Cullinan Therapeutics has scheduled its 2025 Annual Meeting for June 12, 2025, and is seeking stockholder votes on director elections, auditor ratification, and executive compensation.
NASDAQ
Cullinan Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring director elections, auditor ratification, and executive compensation advisory votes.
NASDAQ
Cullinan Therapeutics has scheduled its annual stockholder meeting for June 26, 2024, featuring proposals for director elections and the ratification of KPMG LLP as the independent accounting firm.
NASDAQ
Cullinan Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to vote on the election of directors and the ratification of the company's independent auditor.